scholarly journals The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies

2021 ◽  
Vol 12 ◽  
Author(s):  
Chengmin Yang ◽  
Jing Tang ◽  
Naici Liu ◽  
Li Yao ◽  
Mengyuan Xu ◽  
...  

A large number of neuroimaging studies have detected brain abnormalities in first-episode schizophrenia both before and after treatment, but it remains unclear how these abnormalities reflect the effects of antipsychotic treatment on the brain. To summarize the findings in this regard and provide potential directions for future work, we reviewed longitudinal structural and functional imaging studies in patients with first-episode schizophrenia before and after antipsychotic treatment. A total of 36 neuroimaging studies was included, involving 21 structural imaging studies and 15 functional imaging studies. Both anatomical and functional brain changes in patients after treatment were consistently observed in the frontal and temporal lobes, basal ganglia, limbic system and several key components within the default mode network (DMN). Alterations in these regions were affected by factors such as antipsychotic type, course of treatment, and duration of untreated psychosis (DUP). Over all we showed that: (a) The striatum and DMN were core target regions of treatment in schizophrenia, and their changes were related to different antipsychotics; (b) The gray matter of frontal and temporal lobes tended to reduce after long-term treatment; and (c) Longer DUP was accompanied with faster hippocampal atrophy after initial treatment, which was also associated with poorer outcome. These findings are in accordance with previous notions but should be interpreted with caution. Future studies are needed to clarify the effects of different antipsychotics in multiple conditions and to identify imaging or other biomarkers that may predict antipsychotic treatment response. With such progress, it may help choose effective pharmacological interventional strategies for individuals experiencing recent-onset schizophrenia.

2009 ◽  
Vol 172 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Sarah K. Keedy ◽  
Cherise Rosen ◽  
Tin Khine ◽  
Rajaprabhakaran Rajarethinam ◽  
Philip G. Janicak ◽  
...  

2014 ◽  
Vol 154 (1-3) ◽  
pp. 23-29 ◽  
Author(s):  
Lot de Witte ◽  
Jakub Tomasik ◽  
Emanuel Schwarz ◽  
Paul C. Guest ◽  
Hassan Rahmoune ◽  
...  

2007 ◽  
Vol 191 (4) ◽  
pp. 325-334 ◽  
Author(s):  
Jean Théberge ◽  
Kate E. Williamson ◽  
Naoko Aoyama ◽  
Dick J. Drost ◽  
Rahul Manchanda ◽  
...  

BackgroundProgressive volumetric changes in the brains of people with schizophrenia have been attributed to a number of factors.AimsTo determine whether glutamatergic changes in patients with schizophrenia correlated with grey-matter losses during the first years of illness.MethodLeft anterior cingulate and thalamic glutamatergic metabolite levels and grey-matter volumes were examined in 16 patients with first-episode schizophrenia before and after 10 months and 30 months of antipsychotic treatment and in 16 healthy participants on two occasions 30 months apart.ResultsHigher than normal glutamine levels were found in the anterior cingulate and thalamus of never-treated patients. Thalamic levels of glutamine were significantly reduced after 30 months. Limited grey-matter reductions were seen in patients at 10 months followed by widespread grey-matter loss at 30 months. Parietal and temporal lobe grey-matter loss was correlated with thalamic glutamine loss.ConclusionsElevated glutamine levels in never-treated patients followed by decreased thalamic glutamine and grey-matter loss in connected regions could indicate either neurodegeneration or a plastic response to reduced subcortical activity.


2004 ◽  
Vol 254 (2) ◽  
pp. 129-140 ◽  
Author(s):  
Wolfgang Gaebel ◽  
Hans-Jürgen Möller ◽  
Gerd Buchkremer ◽  
Christian Ohmann ◽  
Mathias Riesbeck ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document